Table 1 Overview of basic characteristics of kidney, heart failure and cardiovascular outcome studies completed in 2020
From: Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Study name | Study status | Drug | Drug class | Intervention | Primary outcome | n | Follow up [years] | Start and end date | Clinicaltrials.gov ID |
|---|---|---|---|---|---|---|---|---|---|
VERTIS-CV [23] | Completed | Ertugliflozin | SGLT-2 inhibitor | Ertugliflozine 5 mg or 15 mg once daily vs. placebo | Composite outcome of MACE (CV death, nonfatal MI, nonfatal stroke) | 8246 | 3.5 | 11.2013–12.2019 | NCT01986881 |
DAPA-CKD [29] | Completed | Dapagliflozin | SGLT-2 inhibitor | Dapagliflozine 10 mg once daily vs. placebo | Composite of sustained ≥ 50% eGFR decline, end-stage kidney disease, and renal or CV death | 4304 | 2.4 | 01.2017–08.2020 | NCT03036150 |
EMPEROR-Reduced [30] | Completed | Empagliflozin | SGLT-2 inhibitor | Empagliflozine 10 mg once daily vs. placebo | Composite of CV death or hospitalisation for HF | 3730 | 1.3 | 02.2017–08.2020 | NCT03057977 |
FIDELIO-DKD [32] | Completed | Finerenone | Mineralocorticoid receptor antagonist | Finerenone 10 mg or 20 mg once daily vs. placebo | Composite of onset of kidney failure, sustained ≥ 40% eGFR decline or renal death | 5734 | 2.6 | 07.2015–04.2020 | NCT02540993 |
SOLOIST-WHF [31] | Completed | Sotagliflozin | SGLT-2 Inhibitor | Sotagliflozin 200 mg or 400 mg once daily vs. placebo | Total occurrences of CV death, HHF, and urgent visits for HF | 1222 | 0.7 | 06.2018–06.2020 | NCT03521934 |
SCORED [28] | Completed | Sotagliflozin | SGLT-2 Inhibitor | Sotagliflozin 200 mg or 400 mg once daily vs. placebo | Total occurrences of CV death, HHF, and urgent visits for HF | 10584 | 1.3 | 11.2017–07.2020 | NCT03315143 |